Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis (ID1603)

£656.3K GBP

Funder	National Institute for Health Research
Recipient Organization	Bmj Publishing Group Limited
Country	United Kingdom
Start Date	Jan 19, 2021
End Date	Jul 06, 2021
Duration	168 days
Number of Grantees	1
Roles	Award Holder
Data Source	Europe PMC
Grant ID	`NIHR133239`

Grant Description

To appraise the clinical and cost effectiveness of tanezumab within its marketing authorisation for treating moderate to severe chronic pain caused by osteoarthritis.